Universal Beteiligungs und Servicegesellschaft mbH Invests $28.27 Million in Hologic, Inc. (NASDAQ:HOLX)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 392,133 shares of the medical equipment provider's stock, valued at approximately $28,269,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.17% of Hologic at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Barclays PLC grew its stake in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after purchasing an additional 231,578 shares in the last quarter. LaFleur & Godfrey LLC grew its stake in Hologic by 2.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock worth $9,399,000 after purchasing an additional 3,655 shares in the last quarter. Blue Trust Inc. grew its stake in Hologic by 18.4% during the 4th quarter. Blue Trust Inc. now owns 8,428 shares of the medical equipment provider's stock worth $608,000 after purchasing an additional 1,310 shares in the last quarter. KBC Group NV grew its stake in Hologic by 6.6% during the 4th quarter. KBC Group NV now owns 93,376 shares of the medical equipment provider's stock worth $6,731,000 after purchasing an additional 5,747 shares in the last quarter. Finally, Custom Index Systems LLC grew its stake in Hologic by 7.1% during the 4th quarter. Custom Index Systems LLC now owns 9,379 shares of the medical equipment provider's stock worth $676,000 after purchasing an additional 618 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on HOLX shares. Raymond James reissued an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Evercore ISI decreased their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Stephens decreased their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Finally, Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $77.42.

Hologic Stock Performance

Shares of Hologic stock traded down $0.16 on Monday, hitting $62.01. The stock had a trading volume of 2,584,438 shares, compared to its average volume of 2,269,873. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.82 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 2.14 and a beta of 0.54. The company's 50 day moving average price is $58.15 and its 200 day moving average price is $65.69.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.03 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.88% of the stock is currently owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.